|1.||Visseren, Frank L J: 3 articles (10/2014 - 10/2013)|
|2.||de Kleijn, Dominique P V: 3 articles (10/2014 - 10/2013)|
|3.||Pasterkamp, Gerard: 3 articles (10/2014 - 10/2013)|
|4.||Uiterwaal, Cuno S P M: 3 articles (10/2014 - 10/2013)|
|5.||Uitte de Willige, Shirley: 2 articles (01/2015 - 06/2011)|
|6.||Schoneveld, Arjan H: 2 articles (10/2014 - 10/2013)|
|7.||Philippou, Helen: 2 articles (09/2014 - 06/2011)|
|8.||Kanhai, Danny A: 2 articles (01/2014 - 10/2013)|
|9.||SMART Study Group: 2 articles (01/2014 - 10/2013)|
|10.||van der Graaf, Yolanda: 2 articles (01/2014 - 10/2013)|
01/01/1988 - "3) The plasmin-alpha 2-plasmin inhibitor complex in toxemia was significantly greater than that in normal pregnancy (p less than 0.001), and became very high as the severity of toxemia increased (p less than 0.05). "
01/01/1988 - "In the mild toxemia group, the plasmin-alpha 2-plasmin inhibitor complex became greater as AT-III decreased and a significant negative correlation was observed (r = -0.59, p less than 0.05), whereas in severe toxemia, the complex did not increase as AT-III decreased and no correlation could be observed. "
11/01/1990 - "In this study, blood coagulation and fibrinolytic parameters were measured in maternal blood and fetal umbilical cord blood in 200 normal pregnant women and in 46 with severe toxemia of pregnancy (Toxemia), and the relationships between fetal growth and concentrations protein C (PC), antithrombin-III (AT-III) and alpha 2-plasmin inhibitor (alpha 2-PI) were studied. "
01/01/1988 - "The levels of plasminogen, alpha 2-plasmin inhibitor and factor XIII decreased and plasma bradykinin increased in toxemia. "
01/01/1983 - "In severe toxemia of pregnancy, decreases in extrinsic coagulation factors, platelet, antithrombin III, plasminogen, alpha 2-plasmin inhibitor, and increases in soluble fibrin-monomer complex, fibrin degradation products, beta-thromboglobulin were observed. "
05/01/1997 - "Severe postadenoidectomy bleeding revealing congenital alpha 2 antiplasmin deficiency in a child."
11/01/2001 - "All patients with alpha(2)-plasmin inhibitor activity less than 60% showed a marked bleeding tendency and/or severe brain edema. "
01/01/1991 - "Congenital alpha 2-plasmin inhibitor deficiency is very rare, but causes bleeding problems similar to hemophilia. "
01/01/1985 - "Alpha-2-antiplasmin deficiency may well contribute to the bleeding disorder in acute promyelocytic leukemia."
06/01/1982 - "Six exhibited a mild hemorrhagic diathesis for which no explanation was provided by routine screening of coagulation and platelet functions; also, within the group of heterozygotes, the occurrence of the bleeding tendency did not correlate with differences in residual alpha 2-antiplasmin levels and functions. "
|3.||Ganglion Cysts (Ganglion)
06/01/1997 - "To investigate prospectively whether plasma levels of plasminogen or the ratio of plasminogen to alpha-2-antiplasmin have a prognostic value for survival from sepsis and to study the variation of other hemostatic parameters during septicemia. "
05/01/1991 - "Increased plasminogen activator inhibitor-1 (PAI-1) antigen levels in plasma from patients with septicemia decreased the ratio of the plasma clot lysis rate induced by an anti-alpha 2-plasmin inhibitor monoclonal antibody to the tissue-type plasminogen activator (t-PA) concentration. "
01/01/1992 - "To estimate the degree of coagulopathy in abdominal sepsis, we measured the plasma levels of prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin III complex (TAT) and plasmin-alpha 2-plasmin inhibitor complex (PIC) by the enzyme-linked immunosorbent assay in 38 patients with disseminated intravascular coagulation (DIC). "
01/15/1990 - "Patients defined as having fulminant septicemia (n = 13) with high (greater than 700 ng/L) levels of endotoxin (LPS) in plasma and severe coagulopathy, had significantly lower functional levels of plasminogen (P less than 0.05) and alpha-2-antiplasmin (P less than 0.01) and higher antigen levels of plasminogen activator inhibitor 1 (PAI-1) (P less than 0.01), and fibrin degradation products (FDP) (P less than 0.01), but not of PAI-2 (P greater than 0.1) as compared with less severely ill patients (meningitis and meningococcemia) (n = 25). "
02/01/2000 - "Standard coagulation data and molecular markers of coagulation activation and fibrinolytic activity (soluble thrombomodulin, protein C, free protein S, thrombin/antithrombin III complex, plasmin-alpha 2-antiplasmin complex, tissue plasminogen activator, platelet factor 4, beta-thromboglobulin were measured from arterial blood samples on the day of admission to the intensive care unit (trauma/neurosurgery patients) or on the day of diagnosis of sepsis (baseline value) and serially during the next 5 days. "
|5.||Nephrotic Syndrome (Syndrome, Nephrotic)
01/01/1985 - "Reduced alpha-2-antiplasmin levels in the nephrotic syndrome."
07/01/1991 - "[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]."
02/01/1991 - "Plasma and urine concentrations of factor XIII and its circulating substrates (fibronectin, fibrinogen, and alpha 2-antiplasmin) were measured in a group of 36 patients with nephrotic syndrome. "
03/01/1997 - "[A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer]."
|3.||Antifibrinolytic Agents (Antifibrinolytics)
|4.||fibrin fragment D (D-dimer)
|5.||formycin diphosphate (FDP)
|6.||antithrombin III-protease complex
|4.||Drug Therapy (Chemotherapy)